Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
14 May 2020
14 May 2020
Historique:
received:
09
01
2020
accepted:
19
03
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
22
5
2020
Statut:
epublish
Résumé
Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor
Identifiants
pubmed: 32435414
doi: 10.1021/acsmedchemlett.0c00014
pmc: PMC7236245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
977-983Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM114306
Pays : United States
Informations de copyright
Copyright © 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Med Res Rev. 2020 Jan;40(1):190-244
pubmed: 31218726
Clin Cancer Res. 2019 Sep 1;25(17):5271-5283
pubmed: 30979734
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
pubmed: 16955068
Cancer Sci. 2016 Jul;107(7):955-62
pubmed: 27116120
Leuk Lymphoma. 2018 Jul;59(7):1574-1585
pubmed: 29473431
Oncol Lett. 2017 Nov;14(5):5735-5742
pubmed: 29113202
Cell Death Differ. 2019 May;26(5):890-901
pubmed: 30154449
Sci Rep. 2018 May 31;8(1):8492
pubmed: 29855565
Clin Epigenetics. 2016 Oct 12;8:105
pubmed: 27752293
Adv Cancer Res. 2018;138:183-211
pubmed: 29551127
Int J Biochem Cell Biol. 2015 Dec;69:121-31
pubmed: 26494003
Med Res Rev. 2018 Sep;38(6):2058-2109
pubmed: 29733427
Chem Rec. 2018 Dec;18(12):1818-1832
pubmed: 30338896
Eur J Med Chem. 2016 Aug 8;118:143-60
pubmed: 27128179
Cancer Sci. 2019 Nov;110(11):3442-3452
pubmed: 31432592
Curr Opin Chem Biol. 2019 Jun;50:89-100
pubmed: 30986654
Oncotarget. 2017 Sep 27;8(58):98348-98359
pubmed: 29228694
Lancet Oncol. 2016 May;17(5):622-31
pubmed: 27049457
J Proteomics. 2016 Feb 5;133:125-133
pubmed: 26721445
Bioorg Med Chem. 2017 Jan 1;25(1):27-37
pubmed: 27769671
Cell Death Dis. 2019 Jun 26;10(7):505
pubmed: 31243262
Mol Cancer Ther. 2018 Dec;17(12):2767-2779
pubmed: 30232145
Clin Epigenetics. 2019 Dec 2;11(1):173
pubmed: 31791385
Oncotarget. 2016 Sep 13;7(37):59360-59376
pubmed: 27449082
Oncotarget. 2017 Aug 2;8(40):68557-68570
pubmed: 28978137
J Med Chem. 2019 Apr 11;62(7):3171-3183
pubmed: 30418766
Oncotarget. 2018 Apr 24;9(31):21930-21942
pubmed: 29774113
Oncogene. 2007 Aug 13;26(37):5541-52
pubmed: 17694093
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):
pubmed: 29685965
Cancer Treat Rev. 2014 May;40(4):567-77
pubmed: 24216225